"At least 70% of prostate cancer is located in the peripheral zone, which is exquisitely visualized and targetable with the 70 micron resolution of the ExactVu micro-ultrasound system," says Randy AuCoin, Exact Imaging's President and CEO.

"Our evidence-based PRI-MUS protocol is easily applied to help urologists identify and characterize regions and then to target those suspicious regions. For the minority of cases, such as patients with previous negative biopsies or those with exclusive anterior lesions, Exact Imaging is introducing its FusionVu micro-US/MRI fusion solution.”

 The ExactVu micro-ultrasound platform with FusionVu is a total urological solution and is easily upgradable, scalable and provides a smart, practical investment pathway for urologists.

FusionVu uses an approach called Cognitive Assist whereby the urologist can quickly and easily import radiological reports from MRI scans or import the annotated MR images themselves. These images with MRI-identified lesions are co-aligned with the live ExactVu micro-ultrasound images.

In this way, the urologist can identify and target lesions using PRI-MUS and ExactVu for the majority of cases but, when needed, can also leverage MRI-identified lesions to ensure they are not missed in the total biopsy procedure.

The FusionVu application runs on the the ExactVu platform, does not require any new hardware or radiological software, and is completely focused on the standard urological workflow. It is easy to implement, easy to learn – – because its ultrasound-based – – and cost-effective to implement.